University Medical Center Groningen

Bionano Announces Publication Showing OGM’s High Resolution Structural Variation Detection in Cancer Validated by Cas9-Directed Nanopore Sequencing

Retrieved on: 
Wednesday, April 24, 2024
Nanopore, Nanopore sequencing, OGM, University Medical Center, Doctor of Philosophy, Leukemia, BMA, Genomics, Bone marrow, SVS, SAN, University Medical Center Groningen

OGM has been shown to regularly detect SVs missed by other methods, as a result of the higher resolution and sensitivity of OGM.

Key Points: 
  • OGM has been shown to regularly detect SVs missed by other methods, as a result of the higher resolution and sensitivity of OGM.
  • Some of OGM’s novel findings, however, are difficult for other methods to validate, because of their resolution limitations.
  • The study results highlight OGM’s ability to provide researchers with a more comprehensive understanding of leukemia subtypes and the potential of targeted Cas9-directed Nanopore sequencing to validate new findings efficiently and at high resolution, compared to other genome analysis methods, including short read or other long read sequencing methods.
  • “We were pleased to see researchers conclude that the findings detected by OGM in leukemia samples were robust and superior to classical cytogenetic methods.

Crearene AG and Alzchem Group AG: Successful addition of creatine to dialysis patient treatments

Retrieved on: 
Wednesday, March 13, 2024
Patient safety, Dialysis, Creatine, Trial of the century, University Medical Center Groningen, Research, University Medical Center, Patient, Pharmaceutical industry

Crearene AG and Alzchem Group AG: Successful addition of creatine to dialysis patient treatments

Key Points: 
  • Crearene AG and Alzchem Group AG: Successful addition of creatine to dialysis patient treatments
    As part of their cooperation, Alzchem Group AG and Crearene AG announced in October 2023 that a clinical study on the use of creatine in dialysis treatments had been launched.
  • The aim is to demonstrate the technical feasibility, patient safety and dose finding of creatine-based dialysis treatment solutions.
  • Using specially purified creatine from the Alzchem Group, a University Medical Center Groningen team, led by Prof. Dr. Stephan J.L.
  • Based on the promising initial results, Alzchem Group AG and Crearene AG have extended their collaboration to develop creatine-based treatment solutions for medical applications until the end of 2025.

RaySearch Laboratories: Interim report January 1 - September 30, 2023

Retrieved on: 
Friday, November 17, 2023
Paul Scherrer Institute, CFO, Mass, Cyberknife, CET, University Medical Center Groningen, RaySearch Laboratories, Lausanne University Hospital, University, Partnership, CHUV, Pharmaceutical industry, Nursing, Flour

RaySearch and MedAustron expand their partnership through a new strategic research agreement.

Key Points: 
  • RaySearch and MedAustron expand their partnership through a new strategic research agreement.
  • RaySearch's business partner IBA has placed an order for RayStation and RayCare for installation at CRO National Cancer Institute (C.R.O.)
  • RaySearch has received an order from Israel-based P-Cure and is deepening its collaboration focusing on advanced proton therapy solutions.
  • CEO Johan Löf and interim CFO Annika Blondeau Henriksson will present RaySearch's interim report for January - September 2023 at a webcast to be held in English on Friday, November 17, 2023 at 10:00-10:30 a.m. CET.

RaySearch Laboratories : Interim report January 1 - June 30, 2023

Retrieved on: 
Friday, August 25, 2023
Proton, Cyberknife, Partnership, EU, RaySearch Laboratories, Medical examiner, CEST, Proton therapy, CFO, Research, University Medical Center Groningen, Lausanne University Hospital, Pharmaceutical industry, Flour

New York University Langone Hospital, USA, placed an order for RayStation, which will replace its current treatment planning system.

Key Points: 
  • New York University Langone Hospital, USA, placed an order for RayStation, which will replace its current treatment planning system.
  • Shinva, a Chinese radiation therapy machine manufacturer, placed an order for 15 RayPlan systems for onwards sales to customers in China.
  • The total number of registered shares in RaySearch amounts to 34,282,773 of which 7,654,975 are Class A shares and 26,627,798 are Class B shares.
  • CEO Johan Löf and interim CFO Annika Blondeau Henriksson will present RaySearch's interim report for January -June 2023 at a webcast to be held in English on Friday, August 25, 2023 at 10:00-10:30 a.m. CEST.

UMCG in the Netherlands purchases Micro-RayStation for pre-clinical research, RaySearch Laboratories

Retrieved on: 
Friday, July 7, 2023
RaySearch Laboratories, X-ray, Proton, Monte Carlo, University Medical Center Groningen, Research, Particle, Medical imaging

UMCG has been a RaySearch customer since 2013 and use RayStation as their main treatment planning system for external beam proton and photon radiotherapy.

Key Points: 
  • UMCG has been a RaySearch customer since 2013 and use RayStation as their main treatment planning system for external beam proton and photon radiotherapy.
  • UMCG and RaySearch also have research collaborations together, and the center is part of the RayCare®* advisory board.
  • UMCG will use μ-RayStation for research purposes at the Particle Therapy Research Center ( PARTREC ) irradiation facility under construction at UMCG.
  • Johan Löf, founder and CEO, RaySearch, says: "I am pleased that our long and successful collaboration with UMCG is now being extended to preclinical research.

The Global Prebiotic Association Announces 2023 Young Researcher Fundamental and Applied Research Grant Winners

Retrieved on: 
Friday, April 21, 2023
Single, University, Toll-like receptor, GPA, Synbiotics, Research, Doctor of Philosophy, Groningen, Nutritional science, Journal, Research fellow, University of Groningen, Applied science, Fundamental, Toll, University Medical Center Groningen, Woman, Carbohydrate Polymers, Pharmaceutical industry

CHICAGO, April 21, 2023 /PRNewswire/ -- The Global Prebiotic Association, the only global trade association serving as a resource for prebiotic education, insights, and awareness building, announced today its 2023 Young Researcher grant recipients.

Key Points: 
  • CHICAGO, April 21, 2023 /PRNewswire/ -- The Global Prebiotic Association, the only global trade association serving as a resource for prebiotic education, insights, and awareness building, announced today its 2023 Young Researcher grant recipients.
  • Grants were awarded in two categories – Fundamental and Applied Research.
  • Topics could cover any aspect of prebiotic research (primary authorship) including gut and other microbiomes and must have been original research published in a peer-reviewed journal.
  • The 2024 grant application period will open in November 2023 and will be open to researchers covering prebiotics and synbiotics.

Renalytix and Partners Awarded $10 Million Horizon Europe Grant to Advance Personalized Medicine in Treating CKD Throughout Europe and the United States

Retrieved on: 
Thursday, January 26, 2023
Prognosis, IE, Regent, University Medical Center Groningen, University of Michigan, Institute for Health Metrics and Evaluation, University of Leicester, Biomarker, SALT, European, DE, Valencian Community, Intellectual property, European Medicines Agency, Chronic kidney disease, Research, CKD, University, Patient, HIV disease progression rates, Dialysis, SE, FDA, LSE, Kidney failure, Precision medicine, Kidney disease, Innovative Medicines Initiative, Organization, Joslin Diabetes Center, Pharmaceutical industry

PRIME-CKD is funded by Horizon Europe, the European Union’s key funding program for research and innovation.

Key Points: 
  • PRIME-CKD is funded by Horizon Europe, the European Union’s key funding program for research and innovation.
  • The total budget of the project is $10 million over a projected five-year period with approximately 10% of the budget targeted for commercial translation activities to be undertaken by Renalytix.
  • The consortium brings together leading experts from 11 academic institutions, together with partners from patient representative foundations and regulatory agencies.
  • The PRIME-CKD consortium will further develop the evidence-based tools and roadmap to unlock the potential of precision medicine in the management of CKD.

Albireo to Present Late Breaking Bylvay® (odevixibat) Data at AASLD 2022

Retrieved on: 
Tuesday, November 1, 2022
Population, Liver disease, GLOBE, EC, Department, Health care, Alagille syndrome, Food, Safety, Albert Einstein College of Medicine, Ageing, BSEP, Institute of Liver and Biliary Sciences, Liver, MHRA, Adult, Primary biliary cholangitis, Abdominal pain, Nasdaq, American Association for the Study of Liver Diseases, Incidence, Diarrhea, Digital, University Medical Center Groningen, PFIC, Vomiting, FSV, Biliary atresia, Abstract, BOLD, AASLD, Pediatrics, Public, Diagnosis, Vitamin, Data analysis, Augmented fifth, European Commission, Dehydration, Medicine, ABCB11, 2021 Essex County Council election, Itch, Association, American Association, Pharmaceutical industry, Dietary supplement, Medical imaging, Patient, Montefiore

BOSTON, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today announced the acceptance of two late breakers, including one late breaker with new data from the Phase 3 ASSERT study, to be presented as an oral presentation at the American Association for the Study of Liver Disease (AASLD) The Liver Meeting® 2022, November 4 – 8, 2022. Positive topline results from ASSERT, a global, double-blind, randomized, placebo-controlled trial which evaluated the safety and efficacy of Bylvay in ALGS patients from birth to early adulthood, were announced in October. A second late breaker was also accepted as an oral presentation with data showing Bylvay restored biliary bile acid secretion in treatment-responsive progressive familial intrahepatic cholestasis (PFIC) patients with bile salt export pump (BSEP) deficiency in the PEDFIC 1 trial. A third oral presentation was previously announced, with a pooled data analysis of the PEDFIC trials showing that a decrease in serum bile acids was strongly associated with native liver survival in PFIC patients treated with Bylvay.

Key Points: 
  • A full list of presentations can be found on The Liver Meeting Digital Experience 2022 website .
  • A potent, once-daily, non-systemic ileal bile acid transport inhibitor, Bylvay has minimal systemic exposure and acts locally in the small intestine.
  • The most common adverse reactions for Bylvay are diarrhea, liver test abnormalities, vomiting, abdominal pain, and fat-soluble vitamin deficiency.
  • Bylvay was well tolerated, with an overall adverse event incidence similar to placebo and a low incidence of drug-related diarrhea (11.4% vs. 5.9% placebo).

SHINE Gets Dutch Approval for Project to Improve Patient Access to Promising New Nuclear Medicine

Retrieved on: 
Monday, October 17, 2022
Radionuclide, Union, Delft University of Technology, Nuclear medicine, Terbium, Medicine, University Medical Center Groningen, Transport, Isotope, Royal commission, Hope, CGMP, Patient, Degenerative disease, EANM, SHINE, Cancer, Research, European Commission, Rare-earth element, Medical imaging

VEENDAM, Netherlands and BARCELONA, Spain, Oct. 17, 2022 /PRNewswire/ -- EANM Booth #63 -- SHINE Technologies, a next-generation fusion technology company, and SHINE Europe announced today that the Dutch government has approved a substantial grant proposal to develop a plan to produce a variety of terbium isotopes for use in nuclear medicine.

Key Points: 
  • "Previous collaborations with UMCG and TU Delft have been very fruitful," said Harrie Buurlage, general manager of SHINE Europe.
  • SHINE, a world leader in new high-tech ways to produce medicine, currently produces lutetium-177 in Janesville, Wisconsin (U.S.).
  • SHINE Europe is planning a similar production site in Veendam, the Netherlands, to come online in the next five years.
  • SHINE is a next-generation nuclear technology company deploying advanced fusion technologies to create a scalable path to fusion energy.

SHINE Gets Dutch Approval for Project to Improve Patient Access to Promising New Nuclear Medicine

Retrieved on: 
Monday, October 17, 2022
Radionuclide, Union, Delft University of Technology, Nuclear medicine, Terbium, Medicine, University Medical Center Groningen, Transport, Isotope, Royal commission, Hope, CGMP, Patient, Degenerative disease, EANM, SHINE, Multimedia, Cancer, Research, European Commission, Rare-earth element, Medical imaging

VEENDAM, Netherlands and BARCELONA, Spain, Oct. 17, 2022 /PRNewswire/ -- EANM Booth #63 -- SHINE Technologies, a next-generation fusion technology company, and SHINE Europe announced today that the Dutch government has approved a substantial grant proposal to develop a plan to produce a variety of terbium isotopes for use in nuclear medicine.

Key Points: 
  • "Previous collaborations with UMCG and TU Delft have been very fruitful," said Harrie Buurlage, general manager of SHINE Europe.
  • SHINE, a world leader in new high-tech ways to produce medicine, currently produces lutetium-177 in Janesville, Wisconsin (U.S.).
  • SHINE Europe is planning a similar production site in Veendam, the Netherlands, to come online in the next five years.
  • SHINE is a next-generation nuclear technology company deploying advanced fusion technologies to create a scalable path to fusion energy.